The global tissue engineering market size is expected to
reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a
new report by Grand View Research, Inc. Allogenic tissue transplant method
efficiently addresses challenges and limitations regarding the implementation
and availability of autologous transplants. Moreover, the development of
specialized procedures including implant fixing and sterilization to transform
allogeneic implants so for application as biostatic implants is expected to
drive revenue generation in this market.
Rapid advancements and a strong pipeline of
regenerative medicine are anticipated to provide effective solutions for
chronic conditions. Several companies in growing markets are striving to
capitalize on the untapped market potential with a strong focus on R&D. For
instance, RepliCel is investing in multiple regenerative medicine products. As
of 2019, its three products (RCH-01, RCS-01, RCT-01) were in the development
phase and its dermal injector device (RCI-02) is under pre-commercialization
production and testing phase.
The application of nanotechnology has played a
critical role in the process of tissue engineering. Treating neurological
diseases is a significant challenge as early diagnosis and treatment initiation
is crucial. However, the advent of new 3D designed nanofibers has proved to be
a ready alternative to aid the regeneration of damaged neurons. Such advances
have propelled the growth of tissue engineering products.
Browse full research report on Tissue
Engineering Market:
https://www.grandviewresearch.com/industry-analysis/tissue-engineering-and-regeneration-industry
Further key
findings from the report suggest:
- Cardiology and vascular application is one of
the fastest-growing segments owing to an increasing incidence rate of
heart failures worldwide
- Since the past 20 years, cardiac cell therapy
or cardiomyoplasty has been an important focal point of the majority of
the studies aimed at heart disease management through regeneration
- A rise in the number of children with
congenital malformations such as single ventricle anomalies has led to the
growing demand for heart transplantation
- Tissue-engineered organs help address
challenges related to the lack of suitable donor organ and potential side
effects related to the transplantation, thereby driving the tissue
engineering market growth
- Orthopedic, musculoskeletal, and spine segment
accounted for the major revenue share in 2019 and is anticipated to
dominate the market for tissue engineering through 2027
- The high share is attributable to frequent
damage to musculoskeletal tissues or loss of tissue in disease or injury
with limited repair probability
- In addition, a rise in geriatric population,
increasing sports-related injuries, and musculoskeletal disorders is also
responsible for a high share of orthopedic, musculoskeletal, and spine
segment
- The lucrative opportunities proposed by
emerging economies have drawn the attention of global leaders for
investing in the Asia Pacific region. This is attributable to the fastest
growth of the market for tissue engineering in the Asia Pacific region
throughout the forecast period
- Medtronic plc; Zimmer Biomet Holdings, Inc;
Allergan plc; Athersys, Inc; ACell, Inc.; Stryker Corporation; Integra
LifeSciences Corporation; and Baxter International, Inc. are the key
players operating in the market for tissue engineering
- These participants are engaged in strategic
alliances, deals, and development of novel products to sustain their
market share.
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/tissue-engineering-and-regeneration-industry/request/rs1
Grand
View Research has segmented the global tissue engineering market on the basis
of application and region:
Tissue
Engineering Application Outlook (Revenue, USD Million, 2016 - 2027)
- Cord blood &
Cell Banking
- Cancer
- GI, Gynecology
- Dental
- Skin &
Integumentary
- Urology
- Orthopedics,
Musculoskeletal, & Spine
- Neurology
- Cardiology &
Vascular
- Others
Tissue
Engineering Regional Outlook (Revenue, USD Million, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment